A proposed ban on patenting of biological materials has not survived Committee review. The Australian Senate Committee has not recommended proposed amendments to the Patents Act to ban the patenting of biological materials. The Committee’s report on the issue was made available today:
http://www.aph.gov.au/Senate/committee/legcon_ctte/patent_amendment/report/index.htm
The Patent Amendment (Human Genes and Biological Materials) Bill 2010 was initially motivated by controversy surrounding patents held by Myriad Genetics over components of their genetic tests for susceptibility to breast cancer. The Bill’s text, however, went much further than simply limiting the scope of patentability of claims to genes or genetic markers and would have eliminated patent protection for any biological material, no matter how made, if it “existed in nature”. The inexact nature of the intended ban, its damaging effect on the biomedical and biotechnological industries in Australia, as well as the possibility that it violated Australia’s obligations under various international agreements likely contributed to its failure in committee.
This Bill is separate to the larger and more extensive patent reform legislation now before both chambers. The separate and substantially more extensive “Raising the Bar” amendments to the Patent Act are intended to lift the standards of patentability for inventiveness and utility, but will not alter the scope of patentable subject matter.
regards, Bill
PIZZEYS
bbennett@pizzeys.com.au